GlassScriptPhysician profile
Lloyd P Van Winkle
NPI 1306833173
$5,846.94
in general payments reported to CMS, 2019-2025
39 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $369 · 2021: $909 · 2022: $781 · 2023: $938 · 2024: $1,151 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,267 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,267.18 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,261.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $982.68 | 2020-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $586.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $471.04 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $311.77 | 2021 | |
| Merck Sharp & Dohme LLC | $278.28 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $197.51 | 2020-2025 | Shingrix, Arexvy |
| Pfizer INC. | $186.77 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $177.14 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $147.32 | 2019-2024 | Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.00 | 2024-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $112.07 | 2023-2024 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $106.23 | 2024 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $79.74 | 2022-2023 | Contrave, Onzetra Xsail |
| Corium, LLC | $76.82 | 2025 | Azstarys |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Van Winkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.